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Abstract: Chronic hepatitis B virus (HBV) infection is one of the most common causes of hepatocellular carcinoma (HCC), a malignant tumor with high mortality worldwide. One remarkable
clinical feature of HBV-related HCC is that the risk of development is higher in males and postmenopausal females compared to other females. Increasing evidence also indicates that the prognosis
of HBV-associated HCC may involve gender disparity, with females having more favorable outcomes. The proposed mechanism of this gender disparity is thought to be complex and multifactorial.
Attributions have been made to gender differences in behavioral risk factors, host stress, immune
response, psychology, metabolic risk factors, tumor biology, and hormonal factors. Gender disparities
in hormonal factors and stress with consequent incited inflammation and hepatocarcinogenesis in
HBV-related HCC is a particularly burgeoning area of investigation. Clarifying these mechanisms
could provide insight into HBV-related HCC pathogenesis, and potentially provide a target for
prevention and treatment of this disease. Reported herein is a case series involving two families
affected by vertically transmitted chronic hepatitis B, longitudinally observed over multiple decades,
with family members demonstrating discordant outcomes related to HCC, with worse outcomes
among affected males. As a supplement to this case, we review the currently available literature on
gender differences in outcomes from HBV-related HCC. In reporting this case series, we aim to add
our important observation to the current literature and highlight the need for further research in the
mechanisms involved in gender disparity in the prognosis of HBV-related HCC.
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1. Introduction
The hepatitis B virus (HBV) is a non-cytopathic pathogen that can establish chronic infection in the liver [1,2]. Since the advent of the effective HBV vaccine and the widespread
implementation of HBV vaccination programs, the incidence of HBV infection has decreased worldwide [3,4]. Nonetheless, the burden of HBV infection persists; it roughly
affects 2 billion people worldwide, among which approximately 300 million people are
chronically infected [1,2]. Chronic hepatitis B (CHB) is a common cause of both liver cirrhosis and hepatocellular carcinoma (HCC) [1,2,5]. Given its known carcinogenic properties,
HBV accounts for 25% of HCC cases in developed countries and nearly 60% of cases in
developing countries [1,2,6]. Clinical factors that determine the outcomes of chronic HBV
infection, and HCC, thus carry substantial public health importance [2]. Illumination of
this constellation of risk factors and understanding the HBV-related hepatocarcinogenesis
remains an essential goal of HBV research [1].
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There has been significant progress in the understanding of viral chemistry-related
hepatocarcinogenesis and as a result, advances have been made in targeted anti-HBV therapy, which has ultimately decreased the morbidity and mortality associated with chronic
HBV infection [5]. The incidence of HBV-related HCC has also decreased since the advent
of HBV vaccine and antiviral therapy [4,7–10]. Nonetheless, despite successful treatment
of HBV infection with antiviral therapy, persistent risk for HCC has been reported [11–16].
This is a phenomenon that has also been well documented at our high-volume hepatitis B
center. This suggests that factors beyond the genetic make-up of the virus, and therefore
response to target therapy with antivirals, influence the outcome of CHB infection. On
the contrary, host factors may play a larger role in the development and prognosis of
HBV-related HCC. This idea has spiked wide interest in the scientific community [2,17].
It is well established that compared to women, men have a higher incidence of
HCC across varied etiologies, including HBV [6,17–20]. This supports the potential role
for gender-associated differences in risk factor exposures as well as sex-based biological
differences in disease progression [20]. The role of this gender disparity as a prognostic
indicator in HCC has gained increased recognition [6,17,18,21].
Presented herein is a case series involving two families affected by vertically transmitted CHB, longitudinally observed over multiple decades, with family members demonstrating discordant outcomes related to HCC. Worse outcomes were observed among
affected males.
2. Case Series
2.1. Family 1
In 1987, during a community HBV screening, an Asian mother and her three adult
children (two older brothers and a younger sister) were found to be positive for hepatitis B
surface antigen (HBsAg) with HBV genotype C, suggesting perinatal infection. None of
them had human immunodeficiency virus (HIV) or hepatitis C virus (HCV) co-infections.
Upon longitudinal observation, all four patients went on to develop chronic hepatitis B.
Interestingly, their course of CHB-related illness over the following decades was observed
to be different.
After 14 years without complications or antiviral therapy, in the year 2000 and
at 64 years old (y.o), the mother developed fatigue and presented to our institution
for a new patient visit. Further evaluation revealed an alpha-fetoprotein level of 6.7
(normal < 6.1 ng/mL), alanine aminotransferase (ALT) of 29 (normal < 45 IU/L), and an
abdominal magnetic resonance imaging (MRI) with a 2 × 1.5 cm lesion consistent with
HCC in the absence of evidence of cirrhosis or portal hypertension. She was started on
antiviral therapy with Lamivudine, underwent microwave tumor ablation, and remained
well with undetectable HBV DNA levels. However, she went on to have two HCC recurrences (at the age of 69 and at the age of 82), both managed with loco-regional tumor
ablation and continuation of antiviral therapy. Lamivudine was later switched to Tenofovir
disoproxil fumarate (TDF). Thereafter, her three children established care at our institution.
The mother and her children denied significant alcohol consumption. The children were
found to be in low viremic stages with minimal signs of hepatic inflammation, and antiviral
therapy with TDF was started in 2008 in light of their mother’s multiple HCCs. Antiviral
therapy led to undetectable HBV DNA and normalization of liver enzymes. Even so, at
the age of 55, after having been on anti-HBV therapy with undetectable HBV DNA for
5 years, the oldest son presented with chronic fatigue. Abdominal imaging revealed a 2.8
cm HCC. Despite transarterial chemoembolization (TACE) to the tumor and continuation
of antiviral therapy, he progressed to requiring liver transplantation and was listed for one.
Unfortunately, while awaiting liver transplantation he had HCC recurrence a year later
and died within 12 months at the age of 56 (Figure 1).
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Figure 1. Pedigree of one family cluster (family 1) depicting the current clinical status of family
Figure 1. Pedigree of one family cluster (family 1) depicting the current clinical status of family members as of May 2021.
members as of May 2021. Abbreviations: chronic hepatitis B (CHB), hepatocellular carcinoma
Abbreviations:
chronic
hepatitis
B (CHB), hepatocellular carcinoma (HCC), years old (y.o.).
(HCC),
years
old (y.o.).

The second son remained on antiviral therapy and HCC surveillance with abdominal
The second son remained on antiviral therapy and HCC surveillance with abdominal
ultrasound and alpha-fetoprotein every 6 months. After 8 years of successful antiviral
ultrasound and alpha-fetoprotein every 6 months. After 8 years of successful antiviral
therapy, at age 62, he was diagnosed with HCC. He underwent TACE but developed
therapy, at age 62, he was diagnosed with HCC. He underwent TACE but developed rerecurrence 3 months later.
currence 3 months later.
The youngest child, the daughter, now 58 years old, has remained well on antiviral
The youngest child, the daughter, now 58 years old, has remained well on antiviral
therapy with HCC surveillance and without HCC detection to date.
therapy with HCC surveillance and without HCC detection to date.
Currently, the mother and daughter continue to be on antiviral therapy and remain
Currently, the mother and daughter continue to be on antiviral therapy and remain
clinically well. The second son is listed for orthotopic liver transplantation (Figure 1).
clinically well. The second son is listed for orthotopic liver transplantation (Figure 1).
2.2. Family 2
2.2. Family 2
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Figure 2. Pedigree of one family cluster (family 2) depicting the current clinical status of family memFigure 2. Pedigree of one family cluster (family 2) depicting the current clinical status of family
bers as of
2021.
Abbreviations:
HBVHBV
(hepatitis
B virus),
chronic
hepatitis
B (CHB),
hepatocellular
members
asMay
of May
2021.
Abbreviations:
(hepatitis
B virus),
chronic
hepatitis
B (CHB),
hepacarcinoma
(HCC), years
old
(y.o.).
tocellular
carcinoma
(HCC),
years
old (y.o.).

Soon, his two brothers, one older and the other younger, then established care at our
Soon, his two brothers, one older and the other younger, then established care at
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requiring liver transplantation. In family 1, despite having 3 sequential HCCs, the mother
succumbed to the HCC at the young age of 56 and the surviving son with recurrent HCC is
has remained well for over 20 years since her HCC treatment. Her eldest son, however,
listed for liver transplantation. Similarly, in family 2, of the three sons, only the middlesuccumbed to the HCC at the young age of 56 and the surviving son with recurrent HCC
born son died of HCC. The two other sons are on antiviral therapy while their mother has
is listed for liver transplantation. Similarly, in family 2, of the three sons, only the middleremained well as an asymptomatic HBV carrier for over 30 years with no indication for
born son died of HCC. The two other sons are on antiviral therapy while their mother has
antiviral therapy. Not many reports are available on longitudinal observations of family
remained well as an asymptomatic HBV carrier for over 30 years with no indication for
clusters with CHB, but of the ones reviewed, similar observations can be seen [2].
antiviral therapy. Not many reports are available on longitudinal observations of family
Vertical transmission is a common form of acquiring HBV [2]. In the setting of verticlusters with CHB, but of the ones reviewed, similar observations can be seen [2].
cally transmitted HBV, the mother and child possess genetically identical viral genotypes
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while having similar host genomes [2]. Despite this, as shown here, it has been documented
in such families that clinical outcomes from CHB can vary widely, ranging from lifelong
asymptomatic infection to terminal HCC [1]. Of note, these observations occurred with the
achievement of the treatment goal with targeted anti-HBV therapy [1].
The public health burden of hepatitis B underlines the importance of highlighting and
understanding the constellation of risk factors that predispose, as well as affect prognosis of,
chronically infected individuals to HCC [1]. It is well established that HCC predominantly
affects males, with incidences two to four times more common than that in females,
which remains true for HBV-related HCC [6,17,18,22]. Below we explore the published
literature on the role of gender disparity not just as a risk for HBV-related HCC but as a
prognostic indicator.
In a prospective cohort study from Hawaii involving 1206 patients who developed
HCC, though not limited to HBV-related HCC, males developed HCC at a younger age,
had higher MELD scores, and had larger tumor size(s) [17]. Similar observations were
made in a prospective Italian study involving 1834 patients that aimed to ascertain whether
female HCC patients have a better prognosis [21]. Notably, their study found that female
HCC patients were at an older age at diagnosis, more likely to be diagnosed earlier
and via surveillance as opposed to symptoms and, typically had smaller and more well
differentiated tumors as well as a significantly longer survival (median 29 (95% confidence
interval (CI): 24–33) vs. 24 (22–25) months, p = 0.0001). Interestingly, in this study, female
HCC patients were more likely to present with increased levels of alpha-fetoprotein, though
they had a better survival. The study by Yang et al. also reported a statistically significant
survival advantage in women compared to men with HCC, even in the absence of major
differences in disease burden or broad treatment categories [18].
The physiologic mechanisms underlying why males are more susceptible to developing HCC after an HBV infection, and have less favorable prognosis is an important
yet widely unexplored topic [21], especially in the United States. This gender disparity is
thought to be complex, multifactorial, and likely arise from gender differences in behavioral risk factors, hormonal factors, metabolic factors, and tumor biology [17]. Epigenetic
and genetic alterations have also been implicated in the gender disparity in HBV-related
HCC, but the exact mechanisms remain largely unknown and require further investigations [6]. These factors have been extensively reviewed elsewhere and summarized
below [1,2,5,6,17,18,21,23].
3.1. Role of Behavioral Risk Factors in the Gender Disparity in HBV-Related HCC
Observational studies have found that females are more likely to be compliant with
HCC surveillance guidelines as recommended by the American Association for the Study of
Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) [24].
In turn, HCC surveillance is associated with significant improvements in early tumor
detection, receipt of curative therapy, and overall survival in patients with cirrhosis [24].
A growing number of studies also so support the existence of sex differences in several
aspects of consumption of alcohol, an established hepatotoxin and hepatocarcinogen, as
well as alcohol use disorder (AUD) [25]. AUD is more prevalent in men [25–27]. Additionally, men have been reported to be more likely to drink alcohol excessively compared
to women [25,27,28]. Furthermore, in the United States, men are more likely to have an
alcohol-related hospitalization and death secondary to excessive drinking [27].
3.2. Role of Chronic Inflammation in the Gender Disparity in HBV-Related HCC
The pathophysiology of the gender disparities involved in HBV hepatocarcinogenesis,
however, in most of the implicated risk factors stem from their gender differences in
triggering chronic inflammation. Chronic inflammation is a known major contributor to
tumorigenesis [1,2,6]. The pathogenesis of HBV-related HCC is ultimately attributed to
a persistent inflammatory state created by HBV infection, which indirectly leads to the
accumulation of alterations in the host genome that alas confer cell growth advantage [1,29].
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Hepatitis-related inflammatory cytokines, such as interleukin-6 (IL-6) and interleukin1β (IL-1β), have been identified as core promoters of susceptibility to an HBV infection,
persistence of an HBV infection, and the initiation, promotion, and progression of the
development of HBV-related HCC [2,6,29]. Studies have suggested that the effects of
chronic inflammation and inflammatory cytokines on the development and progression
of HBV-related HCC may vary in patients partly due to their gender difference, with
less favorable outcomes seen in males [6]. This has been supported by studies involving
administration of chemical carcinogens, such as diethylnitrosamine (DEN) and carbon
tetrachloride (CCl4), to mice. Gender disparity is seen in mice given DEN [29] and CCl4 [6],
where more apoptosis, necrosis, and compensatory proliferation of hepatic cells was
induced in male mice than in female mice.
3.3. Role of Stress in the Gender Disparity in HBV-Related HCC
Chronic stress, as a risk factor for HBV-related HCC specifically, has been discussed
extensively and thought to be potentially related to the immunologic and inflammatory
reactions incited by the chronic stress [2,30,31]. Furthermore, a study has demonstrated
strong inflammatory profiles due to psychological stress by demonstrating that the patients’
severity of depression independently correlated with higher levels of pro-inflammatory
markers (e.g., IL-6, NF-κB) after undergoing induction of acute stress via the Trier Social
Stress Test [32]. On the contrary, an interesting report attributed the gradual regression
of a Liver Imaging Reporting and Data System (LI-RADS) 4 (probably hepatocellular
carcinoma) lesion to a LI-RADS 1 (favor benignity) lesion in a patient with cirrhosis from
HBV not just to sustained control of viral replication but to diminished stress levels as
well [30]. Gender differences have been identified in the inflammatory response to stress,
with an exaggerated inflammatory response to stress being noted in males compared to
females [32].
3.4. Role of Metabolic Factors in the Gender Disparity in HBV-Related HCC
Gender disparities have also been noted in metabolic risk factors for HCC. Diabetes
and obesity have been linked with excretion of inflammatory cytokines and therefore can
cause hepatic inflammation and oxidative stress resulting in hepatocyte injury and, subsequently HCC [5]. Previous reports found that among men with diabetes, the risk of chronic
nonalcoholic liver disease and HCC is doubled compared to their female counterparts [5].
3.5. Role of Sex Hormones in the Gender Disparity in HBV-Related HCC
Lastly, the role of sex hormones in HBV-related HCC has attracted great attention. The
gender bias in the risk of and progression of HBV-related HCC has generated significant
interest in the scientific community, especially the role of sex hormones in hepatocarcinogenesis [6,18,21]. Hormonal status is known to be important in modulating the risk of liver
cancer [21,22]. An increasing number of studies have suggested that HBV-associated HCC
may be a hormone-responsive malignant tumor [6] and various studies have explored the
mechanisms involved. It has been reported that high levels of serum testosterone in males
with HBV infection are associated with their development of HCC [20,33]. Androgens
have demonstrated a synergistic oncogenic effect with HBV in men but not women [18].
The possible mechanisms through which androgens exert their effects is thought to be
via activation of the androgen receptor (AR) [6] and its subsequent signaling pathways.
Another hypothesized mechanism is via the Wnt signaling cascade, as evidenced by gene
expression analyses and mouse models; however, further investigations are warranted to
elucidate the exact pathways, especially as Wnt inhibitors enter into clinical practice [34].
Further supporting this is the presence of both higher androgen levels and more active
androgen receptor gene alleles among male HBV carriers with an increased risk of HCC [6].
Unlike androgens, previous reports indicate that estrogen may play an important role
in protecting against the development and progression of HBV infections, including the
development of HBV-related HCC, by decreasing HBV RNA transcription and inflamma-
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tory cytokine levels [6,17,18,29,35]. It has been shown in mice studies that estrogens, at
concentrations present in females but not in males, inhibit chemically induced hepatocarcinogenesis by suppressing IL-6 production [29]. A similar mechanism could account for
the gender bias in liver cancer in humans [29]. Whether or not a disparity exists between
the sexes in serum IL-6 levels or in the levels of expression of IL-6 mRNA in the hepatocytes
of HBV-infected liver is not known, but it might be worth investigating [21].
Although a detailed review of the biologic impact of estrogen on HCC is beyond the
scope of this article, at the mechanistic level, estrogen is thought to exert its protective
effects through the estrogen receptor subtype alpha [18]. Estrogen exerts its effects through
three estrogen receptors (ERs): ER-alpha (ERa), ER-beta (ERb), and G protein-coupled
ER. Genome-wide expression and microRNA analyses in patients with HCC have shown
ERa to be a tumor suppressor protein whose expression is inversely correlated with the
presence of HBV infection, tumor size, and disease stage [18]. Reports of preclinical models
reveal that loss of ERa accelerates the development of DEN-induced HCC by promoting
hepatocyte necrosis over apoptosis [18]. Nonetheless, other studies have demonstrated
that variant ER expression predominates in male patients with HCC and predicts worse
survival, especially in those infected with HBV [6,18]. Expression of these variant receptors
increases genomic oxidative damage, c-myc mRNA expression, and genomic instability,
predisposing to carcinogenesis, and heralds ominous prognosis [21]. Another hypothesis
is that estrogens repress HCC growth by inhibiting tumor-associated macrophages and
preventing ERb from interacting with ATP5J, a part of ATPase, thus inhibiting the JAK1STAT6 pathway [18].
Studies on therapies targeting the hormonal sensitivity of HCC have thus far shown
mixed results. Hormonal replacement therapy has been related to a lower risk of developing HCC [18]. However, endocrine therapies using tamoxifen, a type of drug that exerts a
relatively more estrogenic than anti-estrogenic effect in liver tissues, exhibited only modest
beneficial effects in a relatively small population of patients with advanced HCC and sometimes resulted in a worse survival rate and increased negative impacts. Anti-androgenic
drugs, such as flutamide, failed to provide a remarkable survival advantage when applied
in hormone-blocking treatments for HCC and the use of hormonal drugs in patients with
advanced HCC is not currently recommended [6].
3.6. Future Perspective
Further investigations to validate the aforementioned mechanisms, especially the
expression of sex hormone receptors and understanding the signaling pathway they affect,
may offer critical information regarding novel opportunities in gender-related personalized
therapies for treatment and management of CHB and HBV-related HCC, for example,
by emulating a previous study of HCV-related HCC that aimed to evaluate the genderbased (males vs females) ER subtype protein expression in the liver of normals (basal
expression) and further evaluate the changes in the expression of these subtypes in HCVrelated cirrhosis or HCV-related HCC patients [36]. The impact of the gender-associated
ER subtype ratio distribution in the liver can also be studied relative to oncogenic markers
and that may help us to monitor host therapeutic responses, viral clearance, or improved
prognosis during the carcinogenesis process [36].
4. Conclusions
The importance of sex differences in outcomes of HBV-related HCC was highlighted
by the observations in this case series, with females having a better prognosis. Increasing
evidence shows that gender disparity is an important factor that strongly influences the
risk of development and outcomes from HBV-related HCC, including mortality [6,17,21].
The observed disparity may depend on a series of different pathogenic determinants,
including the levels of sex hormones, inflammatory cytokines, and epigenetic and genetic
alternations [6]. The clinical practice/patient care applications of this, however, remain to
be elucidated. In the meantime, it is important that clinicians and researchers alike consider
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the sex of their patients when caring for or designing and administering treatments chronic
hepatitis B and HBV-related HCC because the outcomes will likely differ [22].
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